Latest news with #NeshatAhmadi
Associated Press
30-06-2025
- Business
- Associated Press
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ('the Company' or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of June 30, 2025. The Company's Articles of Association are available on the Company's website # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Contact Adam Lange (Investors) Vice President, Investor Relations [email protected] Neshat Ahmadi (Investors) Investor Relations Manager [email protected] Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications [email protected]
Yahoo
06-06-2025
- Business
- Yahoo
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ('Zealand Pharma') (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme. Each warrant gives the owner the right to subscribe for one newly issued Zealand Pharma share at a prespecified exercise price within the specific predefined time periods before expiration in the warrant programs. For a more detailed description of Zealand Pharma's warrant programs, see the company's Articles of Association, which are available on the website: The exercise price was DKK 224.40 per share for 4,163 of new shares and DKK 90.70 per share for 288,345 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 27,087,068.70. The new shares give rights to dividends and other rights from the time of the respective warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma's general meetings. Zealand Pharma has only one class of shares. The new shares will be admitted to trading on Nasdaq Copenhagen after the capital increase has been registered with the Danish Business Authority. Following registration of the capital increase with the Danish Business Authority, the share capital of Zealand Pharma will be nominally DKK 71,343,804 divided into 71,343,804 shares with a nominal value of DKK 1 each and corresponding to a total of 71,343,804 votes. A full copy of the new and amended Articles of Association can be found at once registered with the Danish Business Authority. # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor RelationsZealand PharmaEmail: alange@ Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@ Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand Pharmaakrassowska@ in to access your portfolio
